The New Immunotherapy Combinations in the Treatment of Advanced Non-Small Cell Lung Cancer: Reality and Perspectives.
In the recent years, immunotherapeutics and specifically immune-checkpoints inhibitors have marked a significant shift in the diagnostic and therapeutic algorithm of non small cell lung cancer (NSCLC), allowing us to use immunotherapy alone or combined to chemotherapy for a great subset of patients. However, new interesting approaches are being presently investigated, immunotherapy combinations being the most promising one. In particular, the combination of anti-PD-1 nivolumab and anti-CTLA-4 ipilimumab has already provided groundbreaking positive results in the advanced NSCLC and other combinations are currently under investigation. Therefore, this paper aims to provide a comprehensive state-of-the-art review about immunotherapeutic combination therapies, alongside with suggestions about future directions. Nivolumab plus ipilimumab represent the most promising immunotherapy combination for the treatment of advanced NSCLC patients; safety, tolerability and efficacy of new immune modulators (in monotherapy and in immune combinations) must be further assessed in future studies.